Clostridioides difficile is an uncommon but quite serious cause of diarrhea, and it is often associated with antibiotics.

New York, USA, May 03, 2023 (GLOBE NEWSWIRE) -- Clostridium difficile Infections Pipeline Analysis Demonstrates 18+ Key Companies at the Horizon Expected to Transform the Treatment Paradigm, Assesses ...

PARSIPPANY, N.J.--(BUSINESS WIRE)--Ferring Pharmaceuticals is celebrating the second anniversary of the launch of REBYOTA ® (fecal microbiota, live – jslm), the first microbiome-based therapy approved ...

The antibiotic vancomycin, recommended as first-line treatment for infection caused by the deadly superbug C. difficile (C. diff), may not be living up to its promise, according to new research. The ...

In a major step toward a precision therapy for Clostridioides difficile (C. diff) infection, researchers at The Hospital for Sick Children (SickKids) have uncovered how the body's bile acids bind to ...

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Clostridium Difficile Infections pipeline constitutes 20+ key companies continuously working towards developing 22+ ...

Rockville, MD, Jan. 23, 2025 (GLOBE NEWSWIRE) -- The global Clostridium difficile infection treatment market has been estimated at US$ 1.24 billion for 2024 and is projected to expand at a CAGR of 6.3 ...

The Key Clostridium Difficile Infections Companies in the market include - Merck & Co, Tillotts Pharma, Astellas Pharma, Pfizer, Vedanta Biosciences, MGB Biopharma ...

The global Clostridium Difficile Infections (CDI) treatment market is poised for significant growth over the next decade. Valued at an impressive USD 809 million in 2023, the market is projected to ...

FDA approved to prevent recurrent C. difficile infection (rCDI), REBYOTA is widely available with a strong drug supply and dedicated manufacturing facility Since launch, Ferring created REBYOTA @ Home ...